

hydrochloride." The latter is the United States Adopted Name (USAN).
Refer to J. Amer. Med. Assoc. 225, 520 (1973).

The synthesis of the compound and the identification of its
psychotropic properties typical of the major tranzuilizers such as
5 chlorpramazine are described in the following patents and publications.

1. Y. H. Wu, et al., J. Med. Chem. 15, 477 (1972) "Psycho-
sedative Agents. 2. 8-(4-Substituted,1-Piperazinylalkyl)-
8-azaspiro[4.5]decane-7,9-diones".
- 10 2. Y. H. Wu, et al., U.S. Patent No. 3,717,634 patented
February 20, 1973. "N-(Heteroarocyclic)piperazinylalkyl-
azaspiroalkanediones".
3. L. E. Allen, et al., Arzneim.-Forsch. 24, Nr. 6, 917-
922 (1974). "Pharmacologic Effects of MJ 9022-1, a
Potential Tranquilizing Agent".
- 15 4. G. L. Sathananthan, et al., Current Therapeutic Research,
18, (5), 701-705 (1975). "MJ 9022: Correlation
Between Neuroleptic Potential and Stereotypy".
- 20 5. Y. H. Wu, et al., U.S. Patent No. 3,976,776 patented
August 24, 1976. "Tranquilizer Process Employing N-
(Heteroarocyclic)piperazinylalkylazaspiroalkanediones".

Summary of the Invention

The process of the present invention is intended for the
palliative treatment of neurosis with buspirone or a pharmaceutically
acceptable acid addition salt thereof where anxiety symptoms are
25 prominent. Pharmaceutically acceptable acid addition salts of
buspirone and methods of pharmaceutical formulation are described in

the above patent (2) of Y. H. Wu, et al., U.S. 3,717,634 which is incorporated herein in its entirety by reference. The process is specifically intended for adult patients who present with manifest anxiety characterized by an affective state which may occur under
5 many clinical circumstances and in diverse pathologic contexts. It is also applicable to children in similar circumstances.

Neurosis is a functional nervous disorder without demonstrable physical lesion. Neuroses are defined in "Diagnostic and Statistical Manual of Mental Disorders" 2nd Edition, published by American
10 Psychiatric Association, 1968 (Library of Congress Catalog No. 68-26515) as follows (page 39).

"Anxiety is the chief characteristic of the neuroses. It may be felt and expressed directly, or it may be controlled unconsciously and automatically by conversion, displacement
15 and various other psychological mechanisms. Generally, these mechanisms produce symptoms experienced as subjective distress from which the patient desires relief.

"The neuroses, as contrasted to the psychoses, manifest neither gross distortion or misinterpretation of external
20 reality, nor gross personality disorganization. A possible exception to this is hysterical neurosis, which some believe may occasionally be accompanied by hallucinations and other symptoms encountered in psychoses.

"Traditionally, neurotic patients, however severely
25 handicapped by their symptoms, are not classified as psychotic because they are aware that their mental functioning is disturbed."

Anxiety neurosis is defined in the same reference as follows
(page 39).

5 "This neurosis is characterized by anxious over-concern
extending to panic and frequently associated with somatic
symptoms. Unlike Phobic neurosis (q.v.), anxiety may occur
under any circumstances and is not restricted to specific
situations or objects. This disorder must be distinguished
from normal apprehension or fear, which occurs in realistically
dangerous situations."

10 The present process is concerned with the treatment of
anxiety neuroses, and is to be distinguished from prior psychotherapeutic
processes employing buspirone which dealt with psychoses. The following
definition of psychoses is quoted from the above cited "Diagnostic
and Statistical Manual of Mental Disorders" for the purpose of differ-
15 entiating "psychoses" from "neuroses".

"Patients are described as psychotic when their mental
functioning is sufficiently impaired to interfere grossly
with their capacity to meet the ordinary demands of life.
The impairment may result from a serious distortion in
20 their capacity to recognize reality. Hallucinations and
delusions, for example, may distort their perceptions.
Alterations of mood may be so profound that the patient's
capacity to respond appropriately is grossly impaired.
Deficits in perception, language and memory may be so severe
25 that the patient's capacity for mental grasp of his situation
is effectively lost."

Different classes of drugs have been used in the past for the treatment of neuroses and psychoses and no relationship has developed among the drugs which are applicable to the treatment of these two distinct conditions. The psychoses are mainly treated with the phenothiazines with chlorpromazine being representative of this class. The anti-anxiety agents or anxiolytics are drawn from a number of structural classes but the benzodiazepines, with diazepam as a specific example, include the majority of drugs used for this purpose. Buspirone is structurally unrelated to any other drug used in the treatment of neuroses.

Administration of buspirone according to the present invention may be by the parenteral, oral, or rectal routes. The oral route is, however, preferred and there is, in fact, little need to employ other means of administration such as subcutaneous, intramuscular, or intravenous injection. The reason for this is that neurotic patients for whom the process is applicable are rational individuals, are generally treated on an out-patient basis, and are able to cooperate with the physician or psychiatrist. Generally speaking, the effectiveness of the method soon becomes evident to the patient and ensures his cooperation.

Dosage amounts are less than about 100 mg. per day and preferably in the range of 20-30 mg. per day. In exceptional cases, it may be necessary to increase the dose to about 60 mg. per day. Since the dosage must be tailored to the individual patient, the usual practice is to commence with a dose of 5 mg. administered two or three times per day and to then increase the dose every two or three days by 5 mg. at each dosage time until the desired response is

observed or until the patient complains of side effects. Single daily dosage is applicable in some instances. The duration of treatment is extended until the patient's symptoms have substantially disappeared and a symptom-free period has elapsed. Usual periods of
5 treatment are from one to three months. Treatment may be re-instituted at any time that symptoms reappear.

The dosage range referred to above serves to emphasize the distinction between the present process and the treatment of psychotic patients with buspirone as has been described in the prior art (G. L. Sathananthan, et al. op cit.) in which doses of from 600 to 2400 mg.
10 per day of buspirone hydrochloride were required to demonstrate neuroleptic action in psychotic patients. The dosage range of ¹⁰20 to 100 mg. per day which is applicable to neurotic patients to achieve an anxiolytic effect is without adverse effect in a normal individual
15 and without neuroleptic effect in a psychotic patient for whom treatment with an anti-psychotic agent or major tranquilizer is indicated.

Detailed Description of the Invention

The patients for treatment according to the present invention are minimally characterized by the first two manifestations listed below which are exhibited to a moderate or high degree of severity and preferably at least three of the others listed as (3) through (17).

Subjective Experiences:

- (1) Feeling nervous, jittery, jumpy
(2) Feeling fearful, apprehensive, anxious, panicky

5

(3) Fears of fainting, screaming, losing control, crowds, places, disaster, death

(4) Avoiding certain places, things, or activities because of fear

(5) Feeling tense or keyed up

Muscular or Motor Phenomena:

(6) Tense, aching muscles

(7) Trembling, shaking

(8) Restlessness, fidgeting

10

Autonomic Phenomena:

(9) Heart beating fast or pounding; chest pain

(10) Trouble catching breath, air hunger, smothering, lump in throat, choking

15

(11) Sweating, especially armpits, palms, soles of feet

(12) Cold, clammy hands

(13) Dry mouth

(14) Dizziness, faintness, lightheadedness, weakness

20

(15) Tingling feelings in hands or feet

(16) Stomach "gas", nausea, upset stomach

(17) Frequency or urgency of bladder or bowels

25

The patients are preferably rated before commencing treatment according to one or more of the established psychometric rating scales for neurotic patients. The same psychometric methods may then be used to evaluate the patient periodically during the treatment

period, preferably every 2 or 3 days until the appropriate dosage schedule has been determined and then at weekly intervals.

Various suitable rating scales have been described in the literature. They have been collected in a form readily adapted to clinical use by the U.S. Department of Health, Education and Welfare in a volume by William Guy entitled "ECDEU Assessment Manual for Psychopharmacology", Revised 1976, National Institute of Mental Health, 5600 Fishers Lane, Rockville, Maryland 20852. (DHEW Publication No. (ADM)76-338). ECDEU is an acronym for Early Clinical Drug Evaluation Unit. Some of these psychometric rating scales which are suitable for this invention are listed below. The page numbers refer to the foregoing collection.

	Hamilton Anxiety Scale	page 193
	Hamilton Depression Scale	page 179
15	Self Report Symptom	
	Inventory	page 313
	Profile of Mood States	page 529
	Hopkins Symptom Checklist	page 575
	Self Rating Symptom Scale	page 579
20	Clinical Global Impressions	page 217

Other Rating scales as may suit the physician or psychiatrist may also be employed. Also, other tests as may be deemed desirable by the physician or psychiatrist in accord with good medical practice should be employed such as a complete medical history and physical examination.

Dosage is commenced at from 10 mg. to 20 mg. per day, and then increased step-wise until an anxiolytically effective dose is

achieved without toxic effect. The dose may then be reduced to establish the optimal effect-minimal dose relationship. This usually occurs in the range of 20-30 mg. per day, but doses as high as 60 mg. per day may be employed. Doses as high as about 100 mg. are without
5 substantial adverse effects in normal or neurotic individuals.

Dosage on a b.i.d. or t.i.d. schedule is preferred.

DF-ent
CCW 8 SP
Description of Specific Embodiments

Example 10, Open Study. Thirty patients diagnosed as suffering from anxiety reaction were entered into an evaluation of
10 buspirone hydrochloride for treatment of the condition. Seven of the thirty patients also exhibited significant symptoms of depression in addition to their predominating symptoms of anxiety reaction. The duration of the study was four weeks. Seven patients dropped out of the study and were not included in the analysis of the results. Two
15 of these suffered side effects by the second day of treatment, one was improved by the seventh day of treatment, and the other four were lost to follow-up for unknown reasons. All patients entered into the study had a rating on the Hamilton Anxiety Scale (op. cit.) of at least 18 on entry into the study. Anxiety symptoms had been present
20 for at least a month in all cases, and 19 had suffered the symptoms for a year or more. None of the patients exhibited evidence of schizophrenia, affective psychosis, convulsive disorders, organic brain syndrome, strong sociopathy, drug addiction, or alcoholism. The patients were rated on entry into and at the conclusion of the
25 study and weekly according to the Hamilton Anxiety Scale (HAM-A op. cit.), the Hamilton Depression Scale (HAM-D op. cit.), and by a

physician's questionnaire (PQ) according to which severity of the disease was rated on the following scale: 1 - not ill; 2 - very mild; 3 - mild; 4 - moderate; 5 moderately severe; 6 - severe; 7 - extremely severe. Other rating methods were also used. The following table shows the average daily dose, and the rating scale results. The HAM-A and HAM-D ratings at the end of the study were within the normal range, and the PQ rating indicated only very mild remaining anxiety.

AVERAGE ANXIETY RATINGS AND DOSAGES

	Daily Dose (mg.)	HAM-A	HAM-D	PQ	n ³
Outset	0	21.5	12.1	4.5	23
Week 1	21.3	11.0 ¹	8.8 ²	3.6 ²	23
Week 2	25.1	8.3 ¹	7.4 ²	2.9 ²	16
Week 3	24.1	5.5 ¹	4.8 ¹	2.5 ²	13
Week 4	19.9	2.8 ¹	3.7 ¹	2.3 ²	12

¹Paired t-test relative to outset values significant @ 0.01 level.

²Paired t-test relative to outset values significant @ 0.05 level.

³Number of patients included in evaluation.

CLARK Example 2. Double Blind Study. - Sixty adult out-patients with manifest anxiety were selected for a double-blind parallel study. Twenty patients were entered into each of three groups. One group was treated with buspirone hydrochloride, 5 mg. capsule, another with diazepam, 5 mg. tablet contained within a matching capsule, and the third with placebo, inert ingredients in a matching capsule. The starting dose was one capsule b.i.d. (buspirone hydrochloride 10 mg. or diazepam 10 mg.) and the dose was increased by one

or two capsules every two or three days depending upon therapeutic response and side effects. The maximum dose allowable was 60 mg. per day of buspirone hydrochloride or diazepam. Laboratory and physical examinations were conducted on admission and at termination of the

5 study and a number of standard psychometric rating scales were administered on admission, at weekly intervals, and at termination of the study. The study duration was four weeks. The results based upon the degree of improvement in the physician's evaluation and in the patient's own evaluation are given in the following table. The

10 status of the patients at the end of the study is given, as well as the cumulative results which include drop-outs evaluated at an interim period.

10/20/20

- 12 -

10 RESULTS:

10 RESULTS:

18 2^4

none

18 2^4

15

3. Two dropped out during the first week for unknown reasons; the remainder dropped out subsequently due to lack of improvement.

20

The therapeutic effect with buspirone hydrochloride was comparable to that obtained with diazepam. Buspirone had fewer side effects than either diazepam or placebo. Only three patients complained of side effects under buspirone. These occurred within the first two weeks and only one patient dropped out because of side effects (moderate dizziness, cold sweat). Ten patients complained of side effects under diazepam but only three dropped out for this reason (weakness, tiredness, nausea, vomiting, insomnia, vivid dreams, drowsiness, depression, dry mouth, dizziness, excitement, confusion, tachycardia, tremor, blurred vision, and headache). Six patients complained of side effects under placebo but none dropped out for this reason. Placebo drop-outs were due to lack of therapeutic effect. In addition, buspirone appeared to be effective in relieving depression in patients presenting with mixed anxiety and depression symptoms. Sleep information gathered during the study indicated that the patients slept more deeply under diazepam in contrast to the lighter sleep reported by the buspirone patients. A deeper sleep would accord with the sedation action of diazepam.

Example 3. Buspirone Hydrochloride 5 mg. and 10 mg. Tablets.-

The following ingredients are employed.

	5 mg. Tablet	10 mg. Tablet
Buspirone Hydrochloride	5.0 mg	10.0 mg
Lactose, Anhydrous Direct Compression	55.7	111.4
Starch, Sodium Carboxy-Methyl	8.0	16.0
Cellulose, Microcrystalline, NF	30.0	60.0
Colloidal Silicon Dioxide	0.5	1.0
Magnesium Stearate	0.8	1.6
TOTAL.	100.0	200.0

Processing Instructions:

- 1.0 Blend in a suitable mixer:
 - (a) Colloidal Silicon Dioxide
 - (b) Cellulose, Microcrystalline, NF
- 5 2.0 Pass the blended material from Step 1 through a screen.
- 3.0 Blend in a suitable mixer:
 - (a) Screened powder from Step 2
 - (b) Buspirone Hydrochloride
 - (c) Lactose, Anhydrous DC
 - 10 (d) Starch, Sodium Carboxy-Methyl
 - (e) Cellulose, Microcrystalline, NF
 - (f) Magnesium Stearate
- 4.0 Compress the granulation into tablets.